$51.15
+0.87 (+1.73%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where GSK is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 19 tracked-famous managers (Dodge & Cox, PRIMECAP MANAGEMENT CO/CA/, Point72 Asset Management, L.P., Qube Research & Technologies Ltd, D. E. Shaw & Co., Inc., +14 more) · FINRA short interest 2.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsNCT05489237Phase 1 (Dose Escalation) - Safety and Tolerability (Nature, incidence, and severity of any DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: IDRX-42 | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer | 276 | 2027-03-10 | in 203 d | 2026-07-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19